3-amino-3-(3-bromo-phenyl)-propionic acid methyl ester | 1038381-80-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-amino-3-(3-bromo-phenyl)-propionic acid methyl ester
• 英文别名: Methyl 3-amino-3-(3-bromophenyl)propanoate
• CAS: 1038381-80-4
• 化学式: C₁₀H₁₂BrNO₂
• mdl: MFCD11200706
• 分子量: 258.115
• InChiKey: AYYCGDYJGQKXIO-UHFFFAOYSA-N

物化性质

• 沸点：
  336.4±32.0 °C(Predicted)
• 密度：
  1.439±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氯-3-甲基-1-苯基-1H-吡唑-4-羧酸 、 3-amino-3-(3-bromo-phenyl)-propionic acid methyl ester 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1)

  摘要：

  All-trans-retinoic acid (ATRA), the biologically active metabolite of vitamin A, is used medicinally for the treatment of hyperproliferative diseases and cancers. However, it is easily metabolized. In this study, the leading compound S8 was found based on virtual screening. To improve the activity of the leading compound S8, a series of novel S8 derivatives were designed, synthesized and evaluated for their in vitro biological activities.All of the prepared compounds showed that substituting the 5-chloro-3-methyl-1-phenyl-1H-pyrazole group for the 2-tertbutyl-5-methylfuran scaffold led to a clear increase in the biological activity. The most promising compound 32, with a CYP26A1 IC50 value of 1.36 mu M (compared to liarozole (IC50 = 2.45 mu M) and S8 (IC50 = 3.21 mu M)) displayed strong inhibitory and differentiation activity against HL60 cells. In addition, the study focused on the effect of beta-phenylalanine, which forms the coordination bond with the heme of CYP26A1. These studies suggest that the compound 32 can be used as an appropriate candidate for future development. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.11.036
• 作为产物：
  描述：

  间溴苯甲醛 在 氯化亚砜 、 ammonium acetate 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 3-amino-3-(3-bromo-phenyl)-propionic acid methyl ester
  参考文献：
  名称：

  Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1)

  摘要：

  All-trans-retinoic acid (ATRA), the biologically active metabolite of vitamin A, is used medicinally for the treatment of hyperproliferative diseases and cancers. However, it is easily metabolized. In this study, the leading compound S8 was found based on virtual screening. To improve the activity of the leading compound S8, a series of novel S8 derivatives were designed, synthesized and evaluated for their in vitro biological activities.All of the prepared compounds showed that substituting the 5-chloro-3-methyl-1-phenyl-1H-pyrazole group for the 2-tertbutyl-5-methylfuran scaffold led to a clear increase in the biological activity. The most promising compound 32, with a CYP26A1 IC50 value of 1.36 mu M (compared to liarozole (IC50 = 2.45 mu M) and S8 (IC50 = 3.21 mu M)) displayed strong inhibitory and differentiation activity against HL60 cells. In addition, the study focused on the effect of beta-phenylalanine, which forms the coordination bond with the heme of CYP26A1. These studies suggest that the compound 32 can be used as an appropriate candidate for future development. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.11.036

文献信息

• [EN] PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS<br/>[FR] COMPOSÉS DE PYRAZOLE COMME ANTAGONISTES DE CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009137338A1

  公开（公告）日：2009-11-12

  Disclosed are compounds of the formula I which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  公开的是公式I的化合物，它们可以阻断CCR1与其配体的相互作用，因此可用于治疗通过CCR1的活性介导或维持的各种疾病和疾病，包括类风湿性关节炎和多发性硬化等自身免疫疾病。还公开了包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7)
  申请人：Morphic Therapeutic, Inc.

  公开号：US20190315692A1

  公开（公告）日：2019-10-17

  Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

  揭示了α4β7整合素的小分子拮抗剂，以及使用它们治疗多种特定疾病或病况的方法。
• Pyrazole compounds as CCR1 antagonists
  申请人：Boehringer Ingelheim International GmbH

  公开号：US08293917B2

  公开（公告）日：2012-10-23

  Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  公开了式(I)的化合物，它们可以阻止CCR1与其配体的相互作用，因此可用于治疗通过CCR1的活性介导或维持的多种疾病和障碍，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。还公开了包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• Pyrazole Compounds As CCR1 Antagonists
  申请人：Cook Brian Nicholas

  公开号：US20110230521A1

  公开（公告）日：2011-09-22

  Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  公开了式(I)的化合物，其可以阻止CCR1及其配体之间的相互作用，因此可用于治疗多种由CCR1的活性介导或维持的疾病和障碍，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。还公开了包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• Carboxylic Acid O–H Insertion Reaction of β-Ester Diazos Enabling Synthesis of β-Acyloxy Esters
  作者：Ziyi Li、Xinyu Yao、Xin Zhang、Haibo Mei、Jianlin Han

  DOI：10.1021/acs.joc.2c02023

  日期：2022.11.18

  β-ester diazos and their applications in carboxylic acid O–H insertion reactions have been reported, which afford β-acyloxy esters in excellent yield. Varieties of aryl- and alkyl-substituted diazos are well tolerated in this insertion reaction under mild and convenient conditions. Moreover, structural modification of the natural product and molecular drug can also be achieved in this reaction. This

  已经报道了非稳定化 β-酯重氮化合物的生成及其在羧酸 O-H 插入反应中的应用，从而以优异的收率提供 β-酰氧基酯。在温和方便的条件下，在此插入反应中可以很好地耐受各种芳基和烷基取代的重氮化合物。此外，该反应还可以实现天然产物和分子药物的结构修饰。该方案不仅实现了涉及不稳定β-酯重氮的反应，而且为合成β-酰氧基酯提供了一种有效的策略。